Dataset Information

Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.

ABSTRACT:

SUBMITTER: Liu J

PROVIDER: S-EPMC8684769 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.

Liu Jinbiao J Bodnar Brittany H BH Padhiar Nigam H NH Khan Adil I AI Meng Fengzhen F Saribas Sami S Wang Peng P Wang Xu X McCluskey Elizabeth E Shah Sahil S Zhao Huaqing H Luo Jin Jun JJ Hu Wen-Hui WH Ho Wen-Zhe WZ

Clinical and translational medicine 20211201 12

PMID: 34923762

Similar Datasets

Project description:Currently, neutralizing antibody and vaccine strategies have been developed by targeting the SARS-CoV-2 strain identified during the early phase of the pandemic. Early studies showed that the ability of SARS-CoV-2 RBD or NTD antibodies to elicit infection enhancement in vivo is still controversial. There are growing concerns that the plasma and neutralizing antibodies from convalescent patients or people receiving vaccines mediate ADE of SARS-CoV-2 variants infections in immune cells. Here, we constructed engineered double-mutant variants containing an RBD mutation and D614G in the spike (S) protein and natural epidemic variants to gain insights into the correlation between the mutations in S proteins and the ADE activities and tested whether convalescent plasma and TOP10 neutralizing antibodies in our laboratory mediated the ADE effects of these SARS-CoV-2 variants. We found that one out of 29 convalescent plasma samples caused the ADE effect of pandemic variant B.1.1.7 and that the ADE effect of wild-type SARS-CoV-2 was not detected for any of these plasma samples. Only one antibody, 55A8, from the same batch of convalescent patients mediated the ADE effects of multiple SARS-CoV-2 variants in vitro, including six double-mutant variants and four epidemic variants, suggesting that ADE activities may be closely related to the antibody itself and the SARS-CoV-2 variants' S proteins. Moreover, the ADE activity of 55A8 depended on FcγRII on immune cells, and the introduction of LALA mutations at the Fc end of 55A8 eliminated the ADE effects in vitro, indicating that 55A8LALA may be a clinical drug used to prevent SARS-CoV-2 variants. Altogether, ADE may occur in rare convalescent patients or vaccinees with ADE-active antibodies who are then exposed to a SARS-CoV-2 variant. These data suggested that potential neutralizing antibodies may need to undergo ADE screening tests for SARS-CoV-2 variants, which should aid in the future design of effective antibody-based therapies.

Dataset Information

Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.

Publications

Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets